SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported):
                                 October 3, 2005

                              EVOLVE ONCOLOGY, INC.

               (Exact name of issuer as specified in its charter)

                                    DELAWARE
                 (State or other jurisdiction of incorporation)

                        Commission file number: 000-26511
                            (Commission File Number)

                                   13-4047693
                        (IRS Employer Identification No.)

             19th Floor, 712 Fifth Avenue, New York, NY, 10019-4108
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (212) 897-6849

                                       N/A
          (Former name or former address, if changed since last report)

ITEM  4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANTS

As of October 3, 2005, the Registrant has appointed new auditors. Registrant
terminated F E Hanson Limited as the company's auditor.

Registrant provided F E Hanson Limited, the former accountant, with a copy of
the disclosures it is making herein prior to the filing of this Current Report
on Form 8-K with the Securities and Exchange Commission ("SEC") and requested
that F E Hanson Limited furnish the Registrant a letter addressed to the SEC
stating if F E Hanson Limited does not agree with the representations made
within this report 8-K. The decision to change auditors was approved by the
Board of Directors. The prior accountant did not render any report on the
financial statements for the past two years which contained any adverse opinion
or disclaimer of opinion, or was qualified or modified as to uncertainty, audit
scope or accounting principles. During the Registrant's two most recent fiscal
years and any subsequent interim period preceding the termination there were no
disagreements with the former accountant on any matter of accounting principles
or practices, financial statement disclosure, or auditing scope or procedure.

Simultaneously with the termination of its relationship with F E Hanson
Limited., Registrant retained Chisholm, Bierwolf, Nilson, LLC, as

<PAGE>

registrant's independent auditors. Chisholm, Bierwolf, Nilson, LLC's address
is 533 W, 2600 S, Suite 250, Bountiful, Utah, 84010

The Registrant's Board of Directors approved the appointment of Chisholm,
Bierwolf, Nilson, LLC as the Registrant's independent accountants on October 3,
2005.

During the most recent fiscal year and subsequent interim period, Registrant has
not consulted with Chisholm, Bierwolf, Nilson, LLC regarding (i) either the
application of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might be rendered on
its financial statements, or (ii) any matter that was either the subject of
disagreement on any matter of accounting principles or practices, financial
statement disclosure or auditing scope or procedures or a reportable event (as
defined in Item 304(a)(1)(v) of Regulation S-K).

ITEM  9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

16.2. Registrants letter to Accountants dated April 28, 2005

16.3 Registrants letter to Accountants dated April 29, 2005

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.

                             EVOLVE ONCOLOGY, INC.,
                       A Delaware corporation (Registrant)


DATE: October 3, 2005                         BY: /S/ Alan Bowen
                                                --------------------------------
                                                Chief Financial Officer


                                  Exhibit Index

16.2 Registrants letter to Accountants dated October 3, 2005

16.3 Registrants letter to Accountants dated October 3, 2005
{"company-data": {"conformed-name": "EVOLVE ONCOLOGY INC", "cik": "0001080129", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "0228"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26511", "film-number": "051118681"}, "business-address": {"street1": "151 SOUTH FERRY QUAY", "street2": "LIVERPOOL", "city": "MERSEYSIDE", "state": "X0", "zip": "L34EW", "phone": "011441925846700"}, "mail-address": {"street1": "666 THIRD AVENUE", "street2": "16TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10019"}, "former-company": [{"former-conformed-name": "ONCTHERA INC", "date-changed": "20030730"}, {"former-conformed-name": "CORSPAN INC", "date-changed": "20020305"}, {"former-conformed-name": "LONDON SOFTWARE INDUSTRIES INC", "date-changed": "19990625"}]}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported):
                                 October 3, 2005

                              EVOLVE ONCOLOGY, INC.

               (Exact name of issuer as specified in its charter)

                                    DELAWARE
                 (State or other jurisdiction of incorporation)

                        Commission file number: 000-26511
                            (Commission File Number)

                                   13-4047693
                        (IRS Employer Identification No.)

             19th Floor, 712 Fifth Avenue, New York, NY, 10019-4108
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (212) 897-6849

                                       N/A
          (Former name or former address, if changed since last report)

ITEM  4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANTS

As of October 3, 2005, the Registrant has appointed new auditors. Registrant
terminated F E Hanson Limited as the company's auditor.

Registrant provided F E Hanson Limited, the former accountant, with a copy of
the disclosures it is making herein prior to the filing of this Current Report
on Form 8-K with the Securities and Exchange Commission ("SEC") and requested
that F E Hanson Limited furnish the Registrant a letter addressed to the SEC
stating if F E Hanson Limited does not agree with the representations made
within this report 8-K. The decision to change auditors was approved by the
Board of Directors. The prior accountant did not render any report on the
financial statements for the past two years which contained any adverse opinion
or disclaimer of opinion, or was qualified or modified as to uncertainty, audit
scope or accounting principles. During the Registrant's two most recent fiscal
years and any subsequent interim period preceding the termination there were no
disagreements with the former accountant on any matter of accounting principles
or practices, financial statement disclosure, or auditing scope or procedure.

Simultaneously with the termination of its relationship with F E Hanson
Limited., Registrant retained Chisholm, Bierwolf, Nilson, LLC, as
registrant's independent auditors. Chisholm, Bierwolf, Nilson, LLC's address
is 533 W, 2600 S, Suite 250, Bountiful, Utah, 84010

The Registrant's Board of Directors approved the appointment of Chisholm,
Bierwolf, Nilson, LLC as the Registrant's independent accountants on October 3,
2005.

During the most recent fiscal year and subsequent interim period, Registrant has
not consulted with Chisholm, Bierwolf, Nilson, LLC regarding (i) either the
application of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might be rendered on
its financial statements, or (ii) any matter that was either the subject of
disagreement on any matter of accounting principles or practices, financial
statement disclosure or auditing scope or procedures or a reportable event (as
defined in Item 304(a)(1)(v) of Regulation S-K).

ITEM  9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

16.2. Registrants letter to Accountants dated April 28, 2005

16.3 Registrants letter to Accountants dated April 29, 2005

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.

                             EVOLVE ONCOLOGY, INC.,
                       A Delaware corporation (Registrant)

DATE: October 3, 2005                         BY: /S/ Alan Bowen
                                                --------------------------------
                                                Chief Financial Officer

                                  Exhibit Index

16.2 Registrants letter to Accountants dated October 3, 2005

16.3 Registrants letter to Accountants dated October 3, 2005